Bruker Co. (NASDAQ:BRKR – Free Report) – Investment analysts at Zacks Research decreased their Q3 2025 earnings per share (EPS) estimates for Bruker in a research report issued on Wednesday, September 18th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings per share of $0.94 for the quarter, down from their prior forecast of $0.96. The consensus estimate for Bruker’s current full-year earnings is $2.61 per share.
Bruker (NASDAQ:BRKR – Get Free Report) last released its earnings results on Tuesday, August 6th. The medical research company reported $0.52 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.52. The company had revenue of $800.70 million for the quarter, compared to analyst estimates of $799.44 million. Bruker had a net margin of 11.29% and a return on equity of 24.92%. The firm’s quarterly revenue was up 17.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.50 EPS.
Get Our Latest Research Report on Bruker
Bruker Stock Up 1.7 %
Shares of NASDAQ BRKR opened at $68.32 on Monday. The firm has a market cap of $9.93 billion, a P/E ratio of 24.84, a price-to-earnings-growth ratio of 2.31 and a beta of 1.18. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.75 and a current ratio of 1.65. Bruker has a 1 year low of $53.79 and a 1 year high of $94.86. The firm’s 50 day moving average price is $64.68 and its 200 day moving average price is $72.30.
Hedge Funds Weigh In On Bruker
Several hedge funds and other institutional investors have recently made changes to their positions in BRKR. First Horizon Advisors Inc. raised its position in Bruker by 120.4% in the second quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 218 shares during the period. Rise Advisors LLC acquired a new position in Bruker during the 1st quarter worth approximately $27,000. Neo Ivy Capital Management purchased a new position in Bruker in the 4th quarter worth approximately $30,000. Covestor Ltd grew its position in Bruker by 139.1% in the first quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 210 shares in the last quarter. Finally, Principal Securities Inc. purchased a new stake in shares of Bruker during the fourth quarter valued at approximately $42,000. Institutional investors and hedge funds own 79.52% of the company’s stock.
Bruker Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 16th. Stockholders of record on Monday, September 2nd were given a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.29%. The ex-dividend date of this dividend was Friday, August 30th. Bruker’s payout ratio is currently 7.27%.
Bruker Company Profile
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Read More
- Five stocks we like better than Bruker
- The Significance of Brokerage Rankings in Stock Selection
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- What is Short Interest? How to Use It
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- What to Know About Investing in Penny Stocks
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.